Pathology

Gestalt Diagnostics Announces Expansion of Digital Pathology Education Module to Include Proficiency Testing, Credentialing, and Credential Management

Retrieved on: 
Wednesday, March 20, 2024
Diagnosis, Gestalt, Administration, AP, Education, Organization, Health, Credentialing, Marie Cassidy, Workflow, Patient safety, Pathology, Anatomical pathology, Medical imaging

SPOKANE, Wash., March 20, 2024 /PRNewswire/ -- Gestalt Diagnostics, Inc., a leading provider of (AI)-driven digital pathology solutions, is excited to announce a series of significant enhancements to its educational module and digital pathology solution, within the PathFlow® solution. These advancements underscore Gestalt's commitment to transforming healthcare from every perspective.

Key Points: 
  • Our Education Module now includes proficiency testing, credentialing management, and results comparison features.
  • Our newly expanded Education Module now includes automated, digital evaluation, proficiency testing, credentialing management, and results comparison features.
  • "Our commitment to innovation extends across all facets of pathology, from Anatomic Pathology (AP), Research, and Education to Management and Administrative functions.
  • Additionally, Gestalt supports research and retrospective image and data capture for over 10 million pathology slides.

Stealth BioTherapeutics Presents Data of Novel Compound, SBT-589, in Friedreich's Ataxia Cardiac Models at the Wellcome Trust Mitochondrial Medicine Conference

Retrieved on: 
Tuesday, March 19, 2024
Discovery, Friedreich's ataxia, Death, Hypertrophy, Conditional sentence, Conference, Disease, Mitochondrion, The Company, Mouse, Mortality, Cardiomyopathy, Senior, Heart failure, Mitochondrial disease, Pathology, Stealth, Pharmaceutical industry

NEEDHAM, Mass., March 19, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-589 data demonstrating cardioprotective effects across pre-clinical models of Friedreich's ataxia (FA). The data were presented at the Wellcome Trust Conference on Mitochondrial Medicine – Therapeutic Development, held March 18-20, 2024, in Cambridge, England.

Key Points: 
  • The data were presented at the Wellcome Trust Conference on Mitochondrial Medicine – Therapeutic Development, held March 18-20, 2024, in Cambridge, England.
  • SBT-589 is a promising novel molecule that acts on mitochondrial pathways essential for cellular health and energy production that are impaired in FA cardiomyopathy.
  • "Mitigating heart disease in FA is central to Stealth's ongoing efforts to improve the lives of individuals with FA.
  • The data were presented by Dr. Laura E. Kropp, Senior Manager of Discovery Biology at Stealth, and recipient of the Keith Michael Andrus Cardiac Award from the Friedreich's Ataxia Research Alliance.

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
Tuesday, March 19, 2024
Medicine, Cervical cancer, Patient, Cancer, HPV16, School, Congress, Gynaecology, Risk, Peking Union Medical College, Woman, LEEP, Safety, Gynecologic Oncology (journal), Pathology, Recurrence, Squamous intraepithelial lesion, Acceleration, Research, Șaeș, SGO, Death, National Cancer Center, Vaccination, Molina Healthcare, Annual general meeting, Health, Obstetrics, Hysterectomy, HSIL, Public health, Infection, Incidence, LSIL, HPV, Bleeding, Physician, Birth control

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.

NRMP® Celebrates Match Day for the 2024 Main Residency Match®, Releases Results for Over 44,000 Applicants and Almost 6,400 Residency Programs

Retrieved on: 
Friday, March 15, 2024
Interventional radiology, PGY-1, Internal medicine, Growth, Pathology, Med-Peds, COVID-19, Anne Ferguson-Smith, Internal, Emergency medicine, MD, MBA, Competition (economics), Cardiothoracic surgery, Orthopedic surgery, BSN, Acceptance, Workforce, Physician, Doctor of Health Science, NRMP, Nursing

This year's Match included 44,853 applicants who certified a rank order list ("active applicants") and 41,503 certified positions in 6,395 residency training programs.

Key Points: 
  • This year's Match included 44,853 applicants who certified a rank order list ("active applicants") and 41,503 certified positions in 6,395 residency training programs.
  • A total of 50,413 applicants registered in the 2024 Main Residency Match, an all-time high and increase of 2,257 or 4.7 percent over last year.
  • Increases afforded applicants access to 125 more programs and 1,128 positions which is 2.8 percent more than the 2023 Main Residency Match.
  • Detailed SOAP results will be available in the 2024 Main Residency Match Results and Data Book, which is published in the Spring.

Asep Medical Confirms the Use of AI - Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, Stem cell, Dicarboxylic acid, Dental implant, Health, Dentistry, Gene, University, Chair, UBC, Erosion, Sepsis, Prevalence, Multiple organ dysfunction syndrome, Risk, COVID-19, Inflammation, Patient, Artificial intelligence, Bacteria, DSM-IV codes, AI, Death, Biofilm, Staphylococcus aureus, LASSO, Infection, Pathology, Therapy, ICU, FDA, The Lancet, Peptide

These markets include oral health (dental) care4, wounds5 and chronic rhinosinusitis6, all addressed by Asep peptides that show excellent activity in model infections.

Key Points: 
  • These markets include oral health (dental) care4, wounds5 and chronic rhinosinusitis6, all addressed by Asep peptides that show excellent activity in model infections.
  • AI was also used to simplify the extreme complexity7 of sepsis, which has limited treatments to date.
  • While others are trying to figure out how AI can be best used, we are already using it with amazing success in diagnostics and therapeutics.
  • Asep Inc. is dedicated to leveraging AI's power to improve human health," said Dr. Evan Haney, Chief Scientific Officer of Asep.

Introducing Overjet for Kids: Dental AI that Parents Need

Retrieved on: 
Wednesday, March 13, 2024
Dental care, Radioactive decay, Dentistry, X-ray, Growth, Intelligence, Trust, Diabetes, Patient, History, Tooth decay, Child, Cancer, AI, Outline, CDC, Habit, Crown, Pain, Pathology, Dentist, FDA, Parent, Food

BOSTON, March 13, 2024 /PRNewswire/ -- Overjet, the world-leader in dental AI, today announced the launch of Overjet for Kids: the new standard of dental care for kids. It is the only technology cleared by the U.S. Food and Drug Administration (FDA) to detect, outline, and quantify tooth decay in children ages 4 and above, a critical time to prevent future problems.

Key Points: 
  • BOSTON, March 13, 2024 /PRNewswire/ -- Overjet , the world-leader in dental AI, today announced the launch of Overjet for Kids: the new standard of dental care for kids.
  • The AI is trained to analyze both primary and permanent teeth, which allows Overjet to highlight its findings with colorful outlines that kids and parents can understand.
  • "Every parent wants to be confident that their child is getting the world's best dental care," said Dr. Teresa Dolan, Overjet's Chief Dental Officer.
  • On March 5, Overjet announced it had raised $53 million of Series C funding , the largest investment in the history of dental AI.

FormaPath to unveil new product at upcoming annual meeting of pathologists

Retrieved on: 
Tuesday, March 12, 2024
Comparison, Pathology

ITHACA, N.Y., March 12, 2024 /PRNewswire/ -- FormaPath is excited to return to the United States and Canadian Academy of Pathology Annual Meeting for 2024.

Key Points: 
  • ITHACA, N.Y., March 12, 2024 /PRNewswire/ -- FormaPath is excited to return to the United States and Canadian Academy of Pathology Annual Meeting for 2024.
  • The company is exhibiting with a booth (#208) that will offer an exclusive preview of their new, state-of-the-art, lab automation equipment.
  • Meeting attendees will also be able to view demonstrations of AdiPress, the automated lymph node dissection tool.
  • On tuesday, March 26 at 9:30 AM the company will participate in a poster presentation: Current State of Intra-/Interobserver Accuracy and Reproducibility in Tissue Biopsy Grossing and Comparison to an Automated Vision System (Poster Board #198)

Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research

Retrieved on: 
Tuesday, March 12, 2024
Plasma, Metabolomics, Disease, Multiple sclerosis, CSF, Partnership, Central nervous system, Biomedical Research, Patient, Biomarker, Research, Parkinson's disease, Cerebrospinal fluid, Medicine, Cardiff University, Alzheimer's disease, Pathology, Pharmaceutical industry

MORRISVILLE, N.C., March 12, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a partnership with Cardiff University Centre for Neuropsychiatric Genetics and Genomics, a renowned institution at the forefront of biomedical research. This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).

Key Points: 
  • This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).
  • MS is a neuroinflammatory disorder that affects the central nervous system, giving rise to a range of physical and neuropsychological challenges.
  • For years, the Cardiff University Centre for Neuropsychiatric Genetics and Genomics has been following MS patients and developing cutting-edge tools for clinicians and researchers.
  • To learn more about Metabolon's research and development efforts in neurodegeneration diseases, including Alzheimer's, Parkinson's, and MS, visit https://www.metabolon.com/applications/neuroscience/

Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research

Retrieved on: 
Tuesday, March 12, 2024
Plasma, Metabolomics, Disease, Multiple sclerosis, CSF, Partnership, Central nervous system, Biomedical Research, Patient, Biomarker, Research, Parkinson's disease, Cerebrospinal fluid, Medicine, Cardiff University, Alzheimer's disease, Pathology, Pharmaceutical industry

MORRISVILLE, N.C., March 12, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a partnership with Cardiff University Centre for Neuropsychiatric Genetics and Genomics, a renowned institution at the forefront of biomedical research. This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).

Key Points: 
  • This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).
  • MS is a neuroinflammatory disorder that affects the central nervous system, giving rise to a range of physical and neuropsychological challenges.
  • For years, the Cardiff University Centre for Neuropsychiatric Genetics and Genomics has been following MS patients and developing cutting-edge tools for clinicians and researchers.
  • To learn more about Metabolon's research and development efforts in neurodegeneration diseases, including Alzheimer's, Parkinson's, and MS, visit https://www.metabolon.com/applications/neuroscience/

INTRODUCING BROWNKIND: SKINCARE DESIGNED FOR THE UNIQUE AGING SIGNS OF MELANIN-RICH SKIN

Retrieved on: 
Tuesday, March 12, 2024
Dark, Cream, Hyperpigmentation, Gooseberry, Beauty, Cleanser, Trial of the century, Phyllanthus emblica, Skin, Dermatology, Love, Pathology, Multimedia, Ageing, Cosmetics

NEW YORK, March 12, 2024 /PRNewswire/ -- Today, brownkind proudly announces the launch of its revolutionary skincare line, dedicated to preserving the inherently youthful appearance of brown skin in every shade. With a deep understanding of the dermatological science of melanin-rich skin types (in all tones, from the lightest expression of melanin to black), brownkind seeks to redefine the standard of skincare for the unique concerns and signs of aging for melanin-rich skin.

Key Points: 
  • With a deep understanding of the dermatological science of melanin-rich skin types (in all tones, from the lightest expression of melanin to black), brownkind seeks to redefine the standard of skincare for the unique concerns and signs of aging for melanin-rich skin.
  • "Skin of color has different signs of aging than white skin," said Dr. Gauri Desai.
  • It asks us to understand skin-care as an act of self-love, and to care for our skin with products that are scientifically designed for our specific concerns.
  • brownkind invites people of color to join us in celebrating the beauty of brown skin with our groundbreaking, melanin-targeted skincare line @brownkindskin.